A Study of Cemsidomide and Elranatamab in People With Multiple Myeloma

Full Title

A Phase 1b, Open-Label, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Maximilian Merz’ office at 646-608-3713. 

Protocol
26-206
Phase
Phase I (phase 1)
Disease Status
Relapsed or Refractory
Investigator
Maximilian Merz
Co-Investigators
Saad Z. Usmani
Diseases
Hematology › Multiple Myeloma
Locations
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau
ClinicalTrials.gov ID
NCT07280013
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description